• DOI:10.1016/S0140-6736(10)60354-6
Corpus ID: 22947231

Ziconotide for treatment of severe chronic pain

@article{Schmidtko2010ZiconotideFT,
  title={Ziconotide for treatment of severe chronic pain},
  author={A. Schmidtko and J. L{\"o}tsch and R. Freynhagen and G. Geisslinger},
  journal={The Lancet},
  year={2010},
  volume={375},
  pages={1569-1577}
}

A. Schmidtko, J. Lötsch, +1 author G. Geisslinger

Published 2010

Medicine

The Lancet

Pharmacological management of severe chronic pain is difficult to achieve with currently available analgesic drugs, and remains a large unmet therapeutic need. The synthetic peptide ziconotide has been approved by the US Food and Drug Administration and the European Medicines Agency for intrathecal treatment of patients with severe chronic pain that is refractory to other treatment modalities. Ziconotide is the first member in the new drug class of selective N-type voltage-sensitive calcium… CONTINUE READING

View on Elsevier

alt.kompetenznetz-parkinson.de

Save to Library

Create Alert

Cite

Launch Research Feed